Comparing Moderna’s mRNA-1083 and Pfizer’s dual-target mRNA vaccines for influenza and COVID-19
Abstract This review examines Moderna’s mRNA-1083 and Pfizer/BioNTech’s mRNA-1020/1030 dual-target vaccines for COVID-19 and influenza. Both utilize mRNA technology, demonstrating strong immunogenicity and favorable safety profiles. Moderna’s mRNA-1083 showed superior immune responses, while Pfizer’...
Saved in:
| Main Authors: | Adewunmi Akingbola, Abiodun Adegbesan, Kolade Adegoke, Courage Idahor, Petra Mariaria, Favour Peters, Raolat Adenike Salami, Olajide Ojo, Emmanuel Nwaeze, Owolabi Abdullahi, Joel Chuku |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-05-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-025-01145-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
mRNA Technologies Danger
by: Mikhail V. Supotnitskiy
Published: (2024-11-01) -
Unraveling the potential: mRNA therapeutics in oncology
by: Karol Gawalski, et al.
Published: (2025-08-01) -
Quantifying the phenotypic information in mRNA abundance
by: Evan Maltz, et al.
Published: (2022-08-01) -
Target mRNA abundance dilutes microRNA and siRNA activity
by: Aaron Arvey, et al.
Published: (2010-04-01) -
mRNA turnover rate limits siRNA and microRNA efficacy
by: Erik Larsson, et al.
Published: (2010-11-01)